Literature DB >> 2107895

Prolonged endometrial stimulation associated with oestradiol implants.

K F Gangar1, D Fraser, M I Whitehead, M P Cust.   

Abstract

OBJECTIVE: To provide information on endometrial stimulation after discontinuation of treatment with oestradiol implants.
DESIGN: Long term follow up of withdrawal bleeding patterns in women taking progestogens cyclically every month after oestradiol implant treatment was ended.
SETTING: Specialist menopause clinic.
SUBJECTS: 10 Postmenopausal patients (at least 12 months' amenorrhoea after the last spontaneous period) who were treated with oestradiol implants for typical symptoms of oestrogen deficiency. The oestradiol dose was 50 mg, reimplantation occurring roughly every six months. Patients subsequently either needed to discontinue the hormone treatment for medical reasons or expressed a desire to stop treatment. MAIN OUTCOME MEASURE: Duration of endometrial stimulation--defined as the presence of withdrawal bleeding in response to progestogen given cyclically--after insertion of the last oestradiol implant.
RESULTS: Four patients eventually stopped bleeding, their mean duration of bleeding being 35 months (range 27-43 months). One patient required hysterectomy 26 months after the last implantation because of persistent irregular bleeding despite treatment with high doses of progestogen. Three patients bled for 22, 30, and 36 months and then restarted oestrogen treatment because symptoms returned. The last two patients subsequently continued to bleed 12 and 21 months after the last implantation.
CONCLUSIONS: The duration of endometrial stimulation after implantation can be prolonged, up to 43 months. Insertion of oestradiol implants can carry a long term commitment to the cyclical administration of progestogen and regular withdrawal bleeding if endometrial hyperplasia and carcinoma are to be avoided.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107895      PMCID: PMC1662234          DOI: 10.1136/bmj.300.6722.436

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  9 in total

1.  Symptoms of oestrogen deficiency associated with supraphysiological plasma oestradiol concentrations in women with oestradiol implants.

Authors:  K Gangar; M Cust; M I Whitehead
Journal:  BMJ       Date:  1989-09-02

2.  Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women.

Authors:  M L Padwick; J Endacott; M I Whitehead
Journal:  Am J Obstet Gynecol       Date:  1985-08-15       Impact factor: 8.661

3.  Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.

Authors:  I Persson; H O Adami; L Bergkvist; A Lindgren; B Pettersson; R Hoover; C Schairer
Journal:  BMJ       Date:  1989-01-21

4.  Endometrial disease after treatment with oestrogens and progestogens in the climacteric.

Authors:  M E Paterson; T Wade-Evans; D W Sturdee; M H Thom; J W Studd
Journal:  Br Med J       Date:  1980-03-22

5.  Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women.

Authors:  M Savvas; J W Studd; I Fogelman; M Dooley; J Montgomery; B Murby
Journal:  BMJ       Date:  1988-07-30

6.  The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome.

Authors:  A L Magos; E Brewster; R Singh; T O'Dowd; M Brincat; J W Studd
Journal:  Br J Obstet Gynaecol       Date:  1986-12

7.  Hormonal profiles in postmenopausal women after therapy with subcutaneous implants.

Authors:  M H Thom; W P Collins; J W Studd
Journal:  Br J Obstet Gynaecol       Date:  1981-04

8.  Endometrial responses to transdermal estradiol in postmenopausal women.

Authors:  M I Whitehead; M L Padwick; J Endacott; J Pryse-Davies
Journal:  Am J Obstet Gynecol       Date:  1985-08-15       Impact factor: 8.661

9.  Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study.

Authors:  A Paganini-Hill; R K Ross; B E Henderson
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  9 in total
  1 in total

Review 1.  Hormone replacement therapy in the aged. A state of the art review.

Authors:  S Jacobs; T C Hillard
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.